



Skin Diseases: From Accurate Diagnosis to Novel Therapeutic Approaches, in the Light of Molecular Medicine

Guest Editor:

Dr. Olga Simionescu

Chief of the First Clinic of Dermatology, Department of Dermatology, “Carol Davila” University of Medicine and Pharmacy, Colentina Hospital, 020125 Bucharest, Romania

Deadline for manuscript submissions:

closed (31 January 2023)

Message from the Guest Editor

Medicine in general, and dermatology in particular, has recently made significant progress. A greater understanding of the molecular mechanisms led eventually to better and more accurate reclassifications in dermatology, the medical specialty that undoubtedly consists of the highest number and variety of diseases.

In psoriasis, we are currently experiencing a spring in novel therapeutic approaches that are life-changing for our patients. Although psoriasis remains a problem, great steps forward have been made in understanding this genetic, inflammatory, immunological, proliferative disorder of keratinization.

The efficiency of monoclonal antibodies in bullous diseases and melanoma has started a new era in our understanding of a tailor-made approach to the dermatological/rheumatological patient.

Human skin is indeed a powerful and amazing immune organ. Cutaneous resident cells are fully equipped to provide the best protection of the other human cells' DNA. For example, if we analyse the keratinocyte, we will realize how diligent it can be during its turnover while participating in both acquired and innate immunity.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)